Several alternative therapies for recurrent GC are available, such as ramucirumab, a monoclonal therapeutic antibody that inhibits VEGF-mediated tumor angiogenesis by binding with VEGFR2, alone or in combination with other cancer drugs [22]. This evidence concerns the gene KDR and neoplasm.